Video

Dr. Johnson on the Risks and Benefits Associated with Anti–PD-1 Therapy in Melanoma

Douglas B. Johnson, MD, discusses the risks and benefits associated with anti–PD-1 therapy in patients with stage III resected melanoma.

Douglas B. Johnson, MD, an assistant professor of Medicine and Hematology/Oncology at Vanderbilt University Medical Center, discusses the risks and benefits associated with anti–PD-1 therapy in patients with stage III resected melanoma.

In a recent study that was published in JAMA Oncology, investigators found that of 387 patients with stage III to IV melanoma, 43.2% who received an anti–PD-1 therapy developed chronic immune-related adverse effects (AEs), defined as those that persisted beyond 12 weeks of anti–PD-1 discontinuation. Despite this, anti–PD-1 agents have demonstrated improved outcomes in patients with melanoma and should still be used in treatment, Johnson says.

For a subset of patients who have very low-risk stage III melanoma, however, it is important to consider whether these agents are necessary, Johnson adds. Although these agents can potentially be used in this population, a discussion about the risks vs the benefits is necessary because due to the possibility of chronic AEs, Johnson concludes.

Related Videos
Matthew P. Deek, MD
Thach-Giao Truong, MD
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Cathy Eng, MD, FACP, FASCO
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD
Georgina V. Long, MBBS, PhD, FRACP
Brian I. Rini, MD, FASCO